RECURSION PHARMACEUTICALS, INC. Lessee, Operating Lease, Liability, Undiscounted Excess Amount
RECURSION PHARMACEUTICALS, INC. (RXRX) had Lessee, Operating Lease, Liability, Undiscounted Excess Amount of $13.37 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount · last filed 2026-02-25
- 2025-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $13.37M.
- 2024-12-31: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $20.15M.
- 2024-09-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $17.22M.
- 2024-06-30: Lessee, Operating Lease, Liability, Undiscounted Excess Amount $17.16M.
| Period end | Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-12-31 | $13.37M 10-K · filed 2026-02-25 |
| 2024-12-31 | $20.15M 10-K · filed 2025-02-28 |
| 2024-09-30 | $17.22M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $17.16M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $16.16M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $16.63M 10-K · filed 2024-02-29 |
| 2023-09-30 | $17.39M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $18.47M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $18.33M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $18.09M 10-K · filed 2023-02-27 |
| 2022-09-30 | $18.99M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $20.13M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $13.35M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |